No abstract

Bradford Scholars -how to deposit your paper Overview Copyright check• Check if your publisher allows submission to a repository.• Use the Sherpa RoMEO database if you are not sure about your publisher's position or email openaccess@bradford.ac.uk.

No abstract

ABSTRACT:The imidazotetrazine ring is an acid-stable precursor and prodrug of highly reactive alkyl diazonium ions. We have shown that this reactivity can be managed productively in an aqueous system for the generation of aziridinium ions with 96% efficiency. The new compounds are potent DNA alkylators and have antitumor activity independent of the O6-methylguanine-DNA methyltransferase and DNA mismatch repair constraints that limit the use of Temozolomide. KEYWORDS: Imidazotetrazine, aziridinium, Temozolomide, cancer, 13 C NMR, DNA I midazotetrazine 1 is a fascinating heterocycle, on account of both its chemistry and the therapeutic applications of its derivatives. It forms the core of the anticancer prodrug Temozolomide 1 (1, R = CH 3 ; TMZ). Although TMZ has achieved "blockbuster" status, 2 it remains the lone member of its drug class because of the constraints placed on tumor response to the prodrug by a requirement for DNA mismatch repair (MMR) and resistance mediated through O6-alkylguanine-DNA alkyltransferase (MGMT). Herein we report a strategy that achieves remarkably effective control of the reactive intermediates generated by the imidazotetrazine ring in an aqueous environment, in this example, to generate aziridinium ions. This design achieves compounds that react with DNA but exhibit chemosensitivity independently of MMR and MGMT.At neutral or alkaline pH, imidazotetrazines 1 (e.g., TMZ) act as a source of diazonium ions 2, with few exceptions, ringopening as shown in Scheme 1. 3 Methyldiazonium is released from TMZ and methylates DNA; lethal interaction of this adduct with MMR causes cell death. There are two kinetic parameters that determine the effectiveness of imidazotetrazine prodrugs. The first is the rate of addition of water (or hydroxide ion) to initiate the ring-opening reaction. This is slow at low pH and, thus, confers acid stability and the convenience of oral dosing. 4 The pH-dependence of this reaction also influences distribution of the prodrug around the body: hydrolysis kinetics at pH 7.4 match closely the uptake rate (peak plasma concentration after 30 min) and metabolic half-life (t 1/2 = 1.29 h) in patients. 1,5 The other significant kinetic parameter is the reactivity of the latent electrophile. Hydrolysis of methyldiazonium in a purely chemical system has t 1/2 = 0.39 s. 6 Again, a suboptimal value detracts from clinical effectiveness: ethyldiazonium eliminates or reacts with water before it is able to locate a reactive nucleic acid target site, 7 while longer-lived intermediary electrophiles such as chloronium achieve clinical efficacy. 8 For TMZ, these clinically useful, if not formally optimized, pharmacokinetic properties were achieved serendipitously.In the design of TMZ analogues with altered spectra of activity, we reasoned that a neighboring group participation (NGP)-based mechanism could be employed to control the incipient alkyldiazonium ions. This would serve the dual functions of directing reactivity and delivering an alternative form of damage to DNA. Since the re...

The antitumor prodrug Temozolomide is compromised by its dependence for activity on DNA mismatch repair (MMR) and the repair of the chemosensitive DNA lesion, O6-methylguanine (O6-MeG), by O6-methylguanine-DNA-methyltransferase (EC 2.1.1.63, MGMT). Tumor response is also dependent on wild-type p53. Novel 3-(2-anilinoethyl)-substituted imidazotetrazines are reported that have activity independent of MGMT, MMR and p53. This is achieved through a switch of mechanism so that bioactivity derives from imidazotetrazine-generated arylaziridinium ions that principally modify guanine-N7 sites on DNA. Mono-and bi-functional analogs are reported and a quantitative structureactivity relationship (QSAR) study identified the p-tolyl-substituted bi-functional congener as optimized for potency, MGMT-independence and MMR-independence. NCI60 data show the tumor cell response is distinct from other imidazotetrazines and DNA-guanine-N7 active agents such as nitrogen mustards and cisplatin. The new imidazotetrazine compounds are promising agents for further development and their improved in vitro activity validates the principles on which they were designed.